Understanding When A1c Falls Short

The hemoglobin A1c test measures the percentage of glycated hemoglobin and provides an estimate of average blood glucose over the preceding two to three months. It remains the cornerstone of glycemic assessment in diabetes management. However, its accuracy depends on normal red blood cell physiology, including a consistent red cell lifespan of approximately 120 days and normal hemoglobin structure. Any condition that alters red blood cell survival time, hemoglobin composition, or the glycation process itself can produce misleading A1c values—falsely low or high results that may lead to inappropriate treatment adjustments, missed hyperglycemic episodes, or increased hypoglycemia risk. Research indicates that 10% to 20% of patients with diabetes have a condition that interferes with A1c accuracy (sourced from a systematic review). Recognizing these scenarios is the first step toward using alternative markers effectively. Clinicians must remain vigilant when A1c values do not align with self-monitored blood glucose (SMBG) readings, continuous glucose monitoring (CGM) data, or the patient’s clinical presentation. In such cases, relying solely on A1c can compromise care and patient safety.

Conditions That Compromise A1c Reliability

Hemoglobin Variants and Hemoglobinopathies

Patients with sickle cell trait (HbAS), sickle cell disease (HbSS), thalassemia (alpha or beta), hemoglobin C (HbC), hemoglobin E (HbE), or other hemoglobin variants frequently show abnormal A1c results. Some variants directly interfere with the assay method; for example, hemoglobin S and C can cause falsely low or high readings depending on the specific laboratory technique used (ion-exchange HPLC vs. immunoassay). Other variants alter red blood cell survival time—sickle cell disease shortens red cell lifespan, leading to a falsely low A1c, while some thalassemias may prolong survival or affect hemoglobin concentration. As a result, A1c does not reliably reflect average glucose in these populations. The American Diabetes Association recommends screening for interfering hemoglobins in patients from ethnic groups with high variant prevalence before relying on A1c alone. When a variant is present, alternative serum-based markers or CGM should be used.

Anemia and Blood Loss

Iron-deficiency anemia prolongs the circulation of older red blood cells, causing a falsely elevated A1c. Hemolytic anemia—whether drug-induced, autoimmune, or hereditary—shortens red cell survival and lowers A1c. Recent blood transfusion, acute blood loss, or erythropoietin therapy all disrupt the stable relationship between A1c and true glycemic status. For instance, transfusion of donor red cells with a different glycation history dilutes the patient’s own hemoglobin, producing an unreliable A1c for several months. Clinicians should consider these factors when interpreting A1c values that do not match clinical presentation or SMBG readings. In many anemic patients, a simple complete blood count (CBC) can raise suspicion for an underlying red cell disorder.

Chronic Kidney Disease

Advanced chronic kidney disease (CKD stages 4–5) brings a complex mix of factors that compromise A1c: anemia of chronic disease, altered red cell lifespan due to uremia, and carbamylated hemoglobin from urea interfering with certain A1c assays. The net effect is that A1c often underestimates glycemic control in this population, leading to undertreatment and increased risk of complications. The National Kidney Foundation recommends using glycated albumin or fructosamine as alternatives for dialysis patients. Fructosamine and glycated albumin are not affected by red blood cell turnover and have been validated in ESRD populations.

Pregnancy

Pregnancy induces plasma volume expansion, altered red blood cell turnover, and frequent iron deficiency. These physiologic shifts make A1c less reliable for managing gestational diabetes or preexisting diabetes during pregnancy. Self-monitoring of blood glucose and continuous glucose monitoring remain the standard of care. Glycated albumin has emerged as a useful adjunct in research settings, offering a shorter-term window (2–3 weeks) that aligns better with the rapid changes in glycemic control during gestation. However, its routine clinical use in pregnancy is not yet universal.

Medications

High-dose salicylates (e.g., aspirin >3 g/day), ribavirin, and dapsone can shorten red cell survival and lower A1c. Chronic opioid use may elevate A1c through mechanisms not directly related to glucose. Other drugs such as antiretroviral agents (e.g., some protease inhibitors) and hydroxyurea can alter red cell lifespan or hemoglobin structure. Always review the medication list when A1c seems inconsistent with other glycemic data. A single medication interaction can skew results for weeks.

Other Conditions

Hypertriglyceridemia, severe hyperbilirubinemia, and certain autoimmune hemolytic anemias can also interfere with A1c measurement. Assay methods vary in susceptibility—for example, the newer enzymatic methods are less affected by common interferences than older HPLC methods. Knowing which method the laboratory uses can help identify potential interferences and guide the choice of alternative marker.

Alternative Glycemic Markers: In-Depth Profiles

Fructosamine

Fructosamine measures glycated serum proteins, primarily albumin. Because these proteins turn over faster than red cells (half-life ~14–20 days), fructosamine reflects average glucose over the preceding 2–3 weeks. It is especially useful when A1c is unreliable due to red cell disorders or when a shorter assessment window is needed—for example, after a medication change, during pregnancy, or when monitoring therapy intensification. Normal values are typically <285 µmol/L, but each laboratory sets its own reference range. However, fructosamine levels are affected by serum albumin concentration. Hypoalbuminemia (common in nephrotic syndrome, liver disease, or malnutrition) will falsely lower fructosamine, while dehydration may raise it. Despite this limitation, fructosamine is widely available, inexpensive, and easy to order. Clinicians can trend it over time for a practical gauge of short-term control. A rough conversion: a fructosamine of 330 µmol/L approximates an A1c of ~7%, but individual variability is substantial.

Glycated Albumin

Glycated albumin (GA) refines the concept of fructosamine by quantifying the percentage of albumin that is glycated. This approach removes the confounding effect of total protein concentration. Normal GA levels range from approximately 11% to 16%. GA reflects the same 2–3 week glycemic window and performs reliably in patients with chronic kidney disease, including those on hemodialysis, and in pregnancy. Some studies suggest GA may predict cardiovascular events and nephropathy better than A1c in certain populations (sourced from a cohort study). The main drawbacks are limited availability and higher cost compared to fructosamine. Still, in patients with conditions that render A1c unreliable, GA provides a more accurate picture than A1c, especially when albumin levels are stable.

1,5-Anhydroglucitol

1,5-Anhydroglucitol (1,5-AG, marketed as GlycoMark™) is a monosaccharide that resembles glucose. Kidneys normally reabsorb it, but when blood glucose exceeds the renal threshold (~180 mg/dL), glucose competes with 1,5-AG for reabsorption, leading to its loss in urine. Low serum levels indicate recent hyperglycemic excursions, especially postprandial spikes, over the previous 1–2 weeks. Normal values are ≥10 µg/mL. This marker is ideal for patients with well-controlled fasting glucose but suspected postprandial hyperglycemia. However, it is not useful in advanced chronic kidney disease because renal handling of glucose is impaired, and it is completely invalid in patients taking SGLT2 inhibitors (which intentionally block glucose reabsorption). Glycosuria of pregnancy can also confound results. Despite these limitations, 1,5-AG offers a unique window into short-term glycemic variability that other markers do not provide. It can be particularly helpful when fine-tuning mealtime insulin or GLP-1 agonists.

Continuous Glucose Monitoring Metrics

Continuous glucose monitoring (CGM) provides real-time glucose data and derived metrics that have become powerful alternatives to A1c. The Glucose Management Indicator (GMI) estimates what A1c would be based on average CGM glucose over 14 days and accounts for the lag between CGM and A1c. Time-in-Range (TIR, 70–180 mg/dL) and its complements (Time Above Range, Time Below Range) offer granular, actionable information that retrospective markers cannot match. For patients with hemolytic anemia or hemoglobin variants, CGM can be invaluable because it measures glucose directly without interference from blood cell abnormalities. Professional CGM (blinded or unblinded) is now widely covered for patients on intensive insulin therapy, and coverage is expanding. The ADA’s Standards of Care recommend a TIR target of >70% for most adults with type 1 or type 2 diabetes. CGM also helps identify hypoglycemia and glycemic variability that A1c may mask. Combining CGM with a serum marker provides the most comprehensive assessment.

Practical Application and Selection of Markers

Patient-Specific Factors

  • Kidney function: For CKD stages 3–5, use glycated albumin or fructosamine. Avoid 1,5-AG. A1c can be used with caution but often underestimates glycemia in advanced disease.
  • Anemia: Fructosamine and glycated albumin are not significantly affected by anemia unless serum protein levels are abnormal. CGM is also an excellent option for any anemia type.
  • Hemoglobin variants: Use serum-based markers (fructosamine, GA) or CGM. GMI can serve as a surrogate for A1c when interpreting CGM data.
  • Pregnancy: Self-monitoring and CGM are primary. Glycated albumin is emerging as a supportive tool. Fructosamine has been used but with less evidence in gravid populations.
  • Rapid therapy changes: Short-window markers (fructosamine, GA, 1,5-AG, CGM) respond faster than A1c when adjusting insulin or GLP-1 agonists. Recheck every 2–4 weeks.
  • Cost and accessibility: Fructosamine is inexpensive and widely available. GA and 1,5-AG often require send-out to reference labs and may cost more. CGM devices have upfront costs but are increasingly covered by insurance for appropriate indications, including for patients with hemoglobinopathies.

Interpreting Results

No single alternative marker correlates perfectly with A1c. For example, a fructosamine level around 330 µmol/L roughly corresponds to an A1c of 7%, but individual variability exists. Each marker reflects a different time window, and results may diverge from A1c when glycemic variability is high. The best approach is to trend the same marker over time rather than rely on a single measurement. Combining two markers can provide complementary information: for instance, glycated albumin for average control and 1,5-AG for postprandial spikes. CGM can then verify patterns and guide real-time adjustments. Clinicians should also consider the patient’s clinical context, including diet, medication adherence, and concurrent illnesses. Documenting the reason for using an alternative marker in the medical record improves continuity of care.

Clinical Scenarios: Choosing the Right Marker

Case 1: Sickle Cell Trait with Type 2 Diabetes

A 35-year-old African American man with sickle cell trait (HbAS) has an A1c of 5.8% despite fingerstick readings averaging 180 mg/dL. Suspecting a falsely low A1c, the provider orders glycated albumin, which returns at 20% (equivalent A1c ~8%). Metformin dose is increased appropriately, and follow-up CGM confirms improved time-in-range. This case illustrates how GA can unmask hidden hyperglycemia in the presence of hemoglobin variants. Without the alternative marker, the patient would have remained undertreated, increasing his risk for microvascular complications.

Case 2: Hemodialysis Patient

A 62-year-old woman on hemodialysis for end-stage renal disease has an A1c of 6.0% but experiences fatigue and polyuria. Pre-dialysis glucose averages 220 mg/dL. Fructosamine is 400 µmol/L (normal <285). Because albumin is low (3.0 g/dL), glycated albumin is also checked at 24% (target <20%). The diabetes regimen is intensified, and symptoms improve. This case shows the need for markers unaffected by anemia and ESRD. A1c alone would have indicated reasonable control, leading to clinical inertia.

Case 3: Assessing Postprandial Hyperglycemia

A 50-year-old woman with type 2 diabetes has an A1c of 7.2% and fasting glucose around 130 mg/dL, but she reports frequent post-meal blood glucose readings above 250 mg/dL. Her physician orders 1,5-AG, which returns at 4.0 µg/mL (normal ≥10). This confirms significant postprandial hyperglycemia. By adding a short-acting mealtime insulin, the patient’s postprandial spikes improve, and her 1,5-AG normalizes over the next three weeks. In this case, using a marker sensitive to recent hyperglycemic excursions guided a therapy change that A1c alone might not have prompted. TIR by CGM later confirmed the improvement.

Future Directions and Emerging Markers

Research continues into novel biomarkers such as advanced glycation end products (AGEs) measured by skin autofluorescence, and heat-stable glycated hemoglobin assays that handle variants better. These are not yet ready for routine clinical use. However, the existing trio of fructosamine, glycated albumin, and 1,5-AG, supplemented by CGM metrics, provides a robust toolkit for clinicians facing unreliable A1c results. Professional guidelines from the ADA and the Endocrine Society increasingly acknowledge these alternatives, though they emphasize that clinical judgment should guide selection. Future standardization of glycated albumin and 1,5-AG assays may improve consistency across laboratories and facilitate broader adoption.

Conclusion

A1c remains a valuable and convenient tool, but it is not infallible. Hemoglobinopathies, anemia, chronic kidney disease, pregnancy, and certain medications can render it misleading. Alternative markers—fructosamine, glycated albumin, and 1,5-AG—offer shorter-term glycemic windows and are largely unaffected by red blood cell disturbances. When used correctly and interpreted in context, they empower clinicians to make more accurate treatment decisions. For the highest-risk populations, combining a serum marker with continuous glucose monitoring data provides the most comprehensive view. As awareness grows and testing becomes more accessible, routine use of these alternatives in appropriate clinical scenarios will improve outcomes for patients with diabetes. The key is to recognize when A1c may be unreliable, select the right alternative based on the patient’s specific comorbidities, and trend results over time to guide therapy.